CSL (CMXHF)
OTHER OTC:CMXHF
Want to see CMXHF full AI Analyst Report?
CMXHF Stock Chart & Stats
$97.43
$5.38(3.14%)
At close: 4:00 PM EST
$97.43
$5.38(3.14%)
Day’s Range― - ―
52-Week Range$86.71 - $184.09
Previous CloseN/A
Volume29.00
Average Volume (3M)1.78K
Market Cap
$43.23B
Enterprise Value$54.49B
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.58B
Price to Earnings (P/E)34.1
Beta0.33
Next Earnings
Aug 18, 2026EPS Estimate
2.8Next Dividend Ex-DateN/A
Dividend Yield2.48%
Share Statistics
EPS (TTM)2.98
Shares Outstanding485,318,970
10 Day Avg. Volume4,226
30 Day Avg. Volume1,785
Financial Highlights & Ratios
PEG Ratio1.90
Price to Book (P/B)3.94
Price to Sales (P/S)4.94
P/FCF Ratio29.97
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.47
Enterprise Value/Gross Profit7.14
Enterprise Value/Ebitda10.59
Forecast
1Y Price Target
$150.08Price Target Upside54.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.93
Revenue Forecast (FY)$11.32B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained free cash flow growth and efficient conversion of earnings into cash provide durable funding for R&D, manufacturing capacity, share buybacks and debt reduction. Strong cash conversion increases strategic optionality and resilience to cyclical or policy shocks over the medium term.
High And Sustainable MarginsRobust gross and operating margins reflect pricing power, scale in plasma fractionation and premium product mix. High margins support reinvestment and R&D while providing a buffer against pricing or reimbursement pressure, underpinning longer-term profitability sustainability.
Vertical Integration And Product MomentumOwning plasma collection secures a scarce raw-material supply and creates a barrier to entry. Successful recent launches and pipeline progress (commercial adoption of HEMGENIX/ANDEMBRY and late‑stage assets) diversify revenue and strengthen structural competitive advantage over coming years.
Bears Say
Slowing Revenue Growth And Recent DeclinesTop-line growth has slowed and H1 showed a material decline, reducing operating leverage and making medium-term margin expansion harder. Recovery depends on execution in Ig, China albumin and vaccine normalization, so persistent softness could constrain sustainable growth rates.
Large Impairments And Restructuring CostsSubstantial non‑cash write‑downs and heavy restructuring spending signal portfolio setbacks and impose short‑term reporting volatility. They also consume management attention and may limit near‑term free cash deployment until cost savings and operational fixes are delivered.
Policy And Competitive Pricing PressuresStructural reimbursement reforms, stricter China policies and generic entrants create recurring downside risk to volumes and pricing in core franchises. These secular pressures can compress long‑term revenue visibility and require sustained product and commercial offsets to preserve growth.
CSL News
CMXHF FAQ
What was CSL’s price range in the past 12 months?
CSL lowest stock price was $86.71 and its highest was $184.09 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $43.23B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Aug 18, 2026 which is in 105 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Feb 10, 2026. The company reported $4.03 earnings per share for the quarter, missing the consensus estimate of $4.14 by -$0.11.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Undervalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of $1.613 which represents an annual dividend yield of 2.48%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 2.8.
How many shares outstanding does CSL have?
CSL has 485,318,970 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of $4.03 in its last earnings report, missing expectations of $4.14. Following the earnings report the stock price went down -4.698%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in CMXHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$150.08 (54.04% Upside)
$150.08 (54.04% Upside)
Blogger Sentiment
Bullish
CMXHF Sentiment 84%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.80%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CMXHF Company Deck
CMXHF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: operational strengths (strong cash generation, share buyback expansion, cost-savings progress, solid Vifor performance, successful new product launches and Seqirus commercial gains) are offset by meaningful near-term pressures (H1 revenue decline, major non-cash impairments and one-off restructuring costs, policy-driven weakness in albumin and Ig headwinds, iron generics and KCENTRA competitive pricing). Management emphasizes these impairments are largely non‑cash, that the transformation is delivering tangible savings, and they have maintained full-year guidance while laying out remediation steps for weaker areas. The tone is cautiously constructive but with material near-term risks that require execution in H2 to validate the outlook.View all CMXHF earnings summariesCMXHF Stock 12 Month Forecast
Average Price Target
$150.08
▲(54.04% Upside)
Technical Analysis
Opthea
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
0.05% Insiders
4.89% Mutual Funds
<0.01% Other Institutional Investors
86.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---